



**\$125 Million**  
Follow-On Offering



Joint Bookrunner  
July 2023

## Leerink Partners Serves as Joint Bookrunner for Caribou Biosciences' (Nasdaq: CRBU) \$125 Million Follow-On Offering

### Key Transaction Highlights

- Confidentially launched deal following announcement of Pfizer's \$25 million investment in Caribou at \$5.33 per share in a PIPE on July 6<sup>th</sup>.
- Publicly launched after the close on July 13<sup>th</sup>, concurrently with new Phase 1 ANTLER clinical trial data that had been shared with Pfizer, and priced overnight.
- Well oversubscribed from both new and existing investors.
- Base deal upsized from \$100 million at public launch to \$125 million.
- Transaction consisted of 19,230,769 shares of common stock at a price of \$6.50 per share, representing a 20% discount to last sale and a 22% premium to the price paid by Pfizer on July 6<sup>th</sup>.
- Caribou intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities to fund manufacturing and clinical development of CB-010 and CB-011, IND-enabling activities, manufacturing and clinical development of CB-012, preclinical development of CB-020, ongoing research activities to advance cell therapy platforms and Cas12a chRDNA and other technologies and for general corporate purposes, including working capital, capital expenditures and corporate development.
- This is Leerink Partners' 2<sup>nd</sup> bookrun offering for Caribou Biosciences and 35<sup>th</sup> bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all Leerink Partners distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON  
53 State Street  
40th Floor  
Boston, MA 02109

CHARLOTTE  
2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

NASHVILLE  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

NEW YORK  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

SAN FRANCISCO  
255 California Street  
12th Floor  
San Francisco, CA 94111